 Onig y gallwn y cyfnod ar gyfer o'u amser o'r anolion i'r ati gwybod, ac mae'r anolion arall o rheswm o'r gweithio leisio ymwyaf, oedd ymweld i'r gweithio'r data ac mae'r gweithio'n gwybod yw o'r amser o'r gweithio'r data o'r argylcheddau clynigol, oedd y clynyddu'r clynyddu cyfnod, ac mae'n rhaid i'r gweithio'r gweithio'r gweithio'r clynyddu clynyddu. gyda'n gweld iawn i'r llwytoedd o'n gweld o'r llwytoedd. Felly, mae'n dwych yn gallu chi'n gwybod bod dwi'n gwybod i'w ddwyllfa'n cyfrydau yn y cyfrifio'r traiw sy'n fydd yn y fydd ystyr plwyntol yw'r llwytoedd. Felly mae'r rhai rhai o'r hoffodd o'r rhaid i'r rhaid i hyn yw. One of the bigger ones is by the insight study which is a study looking at both European patients as well as North and South American patients and they've pulled out of that study some data looking at the use of exasamib in relapsed patients and the important thing about that is that they've been able to show that the excellent results we could see with exasamib in the clinical trials also we can recognise and we can see in those patients as well and that's slightly unusual because many of the other drugs when we've looked in the real world data maybe don't show such good results so I think that's really encouraging it's important for patients because they get some confidence that the results may actually apply to them but it's also important for regulatory authorities and the people who pay for drugs because they're always concerned that we may not get the same effect with the drugs when we open to a wider patient population.